Cargando…
Approach toward In Vitro-Based Human Toxicity Effect Factors for the Life Cycle Impact Assessment of Inhaled Low-Solubility Particles
[Image: see text] Today’s scarcity of animal toxicological data for nanomaterials could be lifted by substituting in vivo data with in vitro data to calculate nanomaterials’ effect factors (EF) for Life Cycle Assessment (LCA). Here, we present a step-by-step procedure to calculate in vitro-to-in viv...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227749/ https://www.ncbi.nlm.nih.gov/pubmed/35657801 http://dx.doi.org/10.1021/acs.est.2c01816 |
_version_ | 1784734257069948928 |
---|---|
author | Romeo, Daina Hischier, Roland Nowack, Bernd Wick, Peter |
author_facet | Romeo, Daina Hischier, Roland Nowack, Bernd Wick, Peter |
author_sort | Romeo, Daina |
collection | PubMed |
description | [Image: see text] Today’s scarcity of animal toxicological data for nanomaterials could be lifted by substituting in vivo data with in vitro data to calculate nanomaterials’ effect factors (EF) for Life Cycle Assessment (LCA). Here, we present a step-by-step procedure to calculate in vitro-to-in vivo extrapolation factors to estimate human Benchmark Doses and subsequently in vitro-based EFs for several inhaled nonsoluble nanomaterials. Based on mouse data, the in vitro-based EF of TiO(2) is between 2.76 · 10(–4) and 1.10 · 10(–3) cases/(m(2)/g·kg intake), depending on the aerodynamic size of the particle, which is in good agreement with in vivo-based EFs (1.51 · 10(–4)–5.6 · 10(–2) cases/(m(2)/g·kg intake)). The EF for amorphous silica is in a similar range as for TiO(2), but the result is less robust due to only few in vivo data available. The results based on rat data are very different, confirming the importance of selecting animal species representative of human responses. The discrepancy between in vivo and in vitro animal data in terms of availability and quality limits the coverage of further nanomaterials. Systematic testing on human and animal cells is needed to reduce the variability in toxicological response determined by the differences in experimental conditions, thus helping improve the predictivity of in vitro-to-in vivo extrapolation factors. |
format | Online Article Text |
id | pubmed-9227749 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-92277492022-06-25 Approach toward In Vitro-Based Human Toxicity Effect Factors for the Life Cycle Impact Assessment of Inhaled Low-Solubility Particles Romeo, Daina Hischier, Roland Nowack, Bernd Wick, Peter Environ Sci Technol [Image: see text] Today’s scarcity of animal toxicological data for nanomaterials could be lifted by substituting in vivo data with in vitro data to calculate nanomaterials’ effect factors (EF) for Life Cycle Assessment (LCA). Here, we present a step-by-step procedure to calculate in vitro-to-in vivo extrapolation factors to estimate human Benchmark Doses and subsequently in vitro-based EFs for several inhaled nonsoluble nanomaterials. Based on mouse data, the in vitro-based EF of TiO(2) is between 2.76 · 10(–4) and 1.10 · 10(–3) cases/(m(2)/g·kg intake), depending on the aerodynamic size of the particle, which is in good agreement with in vivo-based EFs (1.51 · 10(–4)–5.6 · 10(–2) cases/(m(2)/g·kg intake)). The EF for amorphous silica is in a similar range as for TiO(2), but the result is less robust due to only few in vivo data available. The results based on rat data are very different, confirming the importance of selecting animal species representative of human responses. The discrepancy between in vivo and in vitro animal data in terms of availability and quality limits the coverage of further nanomaterials. Systematic testing on human and animal cells is needed to reduce the variability in toxicological response determined by the differences in experimental conditions, thus helping improve the predictivity of in vitro-to-in vivo extrapolation factors. American Chemical Society 2022-06-03 2022-06-21 /pmc/articles/PMC9227749/ /pubmed/35657801 http://dx.doi.org/10.1021/acs.est.2c01816 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Romeo, Daina Hischier, Roland Nowack, Bernd Wick, Peter Approach toward In Vitro-Based Human Toxicity Effect Factors for the Life Cycle Impact Assessment of Inhaled Low-Solubility Particles |
title | Approach
toward In Vitro-Based Human Toxicity Effect Factors
for the Life Cycle Impact Assessment of Inhaled Low-Solubility Particles |
title_full | Approach
toward In Vitro-Based Human Toxicity Effect Factors
for the Life Cycle Impact Assessment of Inhaled Low-Solubility Particles |
title_fullStr | Approach
toward In Vitro-Based Human Toxicity Effect Factors
for the Life Cycle Impact Assessment of Inhaled Low-Solubility Particles |
title_full_unstemmed | Approach
toward In Vitro-Based Human Toxicity Effect Factors
for the Life Cycle Impact Assessment of Inhaled Low-Solubility Particles |
title_short | Approach
toward In Vitro-Based Human Toxicity Effect Factors
for the Life Cycle Impact Assessment of Inhaled Low-Solubility Particles |
title_sort | approach
toward in vitro-based human toxicity effect factors
for the life cycle impact assessment of inhaled low-solubility particles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227749/ https://www.ncbi.nlm.nih.gov/pubmed/35657801 http://dx.doi.org/10.1021/acs.est.2c01816 |
work_keys_str_mv | AT romeodaina approachtowardinvitrobasedhumantoxicityeffectfactorsforthelifecycleimpactassessmentofinhaledlowsolubilityparticles AT hischierroland approachtowardinvitrobasedhumantoxicityeffectfactorsforthelifecycleimpactassessmentofinhaledlowsolubilityparticles AT nowackbernd approachtowardinvitrobasedhumantoxicityeffectfactorsforthelifecycleimpactassessmentofinhaledlowsolubilityparticles AT wickpeter approachtowardinvitrobasedhumantoxicityeffectfactorsforthelifecycleimpactassessmentofinhaledlowsolubilityparticles |